April 11, 2006Current Opinion in Nephrology & Hypertension
Asymmetric dimethylarginine: a new player in the pathogenesis of renal disease?
Population
Patients with chronic kidney disease and end-stage renal disease
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
ADMA may identify high-risk CKD patients; leaves open whether targeting it slows progression or reduces CV events.
Structured PICO
P
Population
Patients with chronic kidney disease and end-stage renal disease
O
Outcome
Renal disease progression and cardiovascular complications
Asymmetric dimethylarginine is highlighted as a novel risk factor implicated in renal disease progression and cardiovascular complications in patients with chronic kidney disease.
Cite This Study
Zoccali et al. (2006) studied this question.